Interventional Cardiology Market Size $18.5B to $36.1B (2026–2036) Q2 2026 Updated | Meridian Consensus

Decision-grade Market IntelligenceAny market · any geography

Layers Companies Methodology Pricing About Contact

Healthcare

currentUpdated yesterdayNext refresh May 29Live · since 40d ago

Boardroom-ready · 8 languages

Interventional Cardiology Market

Name: Interventional Cardiology Market
Creator: Meridian Consensus
Published: 2026-04-13T09:20:55.597Z
License: https://www.meridianconsensus.com/editorial-policy

Valued at $18.5B in 2025, growing at 6.3% to $36.1B by 2036. Moderately concentrated; the top three incumbents hold , led by .

Request the preview PDF

A 57-page institutional preview of the Interventional Cardiology Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Takeaways

North America · 46% revenue share ($8.5B)·Abbott Laboratories · 21% share ($3.9B)·IDN / GPO national contracts (Vizient, Premier, HPG) · 41% of market·Growth of $17.6B · 2025–2036

What are you trying to answer?

Smart-routing TOC · 3 intents

U.1

Strategy / corp dev / market entry

Sizing the opportunity

How big is the Interventional Cardiology today, where is it growing fastest, and what is its three-path-triangulated forecast?

Size rigor + forecast →

U.2

Investment / M&A / equity research

Reading the competitive landscape

Who leads the Interventional Cardiology, by how much, and which incumbents are losing share to which challengers?

Competitive landscape →

Full analysis · 30 chapters

Inside the commissioned report.

263+ pages across 30chapters — sizing, segmentation, competitive structure, regional cuts, scenario forecasts, regulatory clearances, M&A timelines. Every angle a senior buyer asks about, in one place.

01 / 306 pp

Executive Brief

Meridian Executive Synthesis, SCQA open, 1-sentence governing thought, 3 MECE key lines, each evidence-backed. The single page institutional buyers read first.

02 / 3014 pp

Executive Briefing

Meridian Market Position (dated, with confidence band), Strategic Planning Assumptions with probability and invalidation triggers, Current-vs-Future State binding shifts, Forecast Architecture compound build with F20 decomposition, Peer Reconciliation cross-firm consensus, Market Lineage Outlook with Pearson ρ correlation.

Same rigor · your market

This published preview · your commissioned report.

8 dimensions · side-by-side

Dimension

This published preview

Your commissioned report

01Market size & forecast

Headline 2025 figure ($18.5B) and 2036 forecast ($36.1B), year-by-year build to 2036.

Same framework applied to your specific niche — year-by-year 2019–2036 build, F1–F21 reconstruction formulas, ±15% peer-variance band, divergence note where peers disagree.

02Competitive landscape

Analyst take · Healthcare desk

The thesis.

By Meridian Consensus Editorial Committee, Editorial Committee

May 22, 2026 · Committee-reviewed

We're tracking a 6.3% compound through 2036, led by Abbott's 21% share in coronary stents and Boston Scientific's TAVR momentum, though reimbursement pressure in Europe and generic DES competition could trim the tail end of that forecast.

Abbott Laboratories held 21% of the $18.5B market at close of 2025, pulling ~$3.9B in sector revenue by our count. Boston Scientific sat at 18% ($3.3B), Medtronic plc at 15% ($2.8B), and Edwards Lifesciences at 10% ($1.85B). The top four control 64% of the field. Coronary stents—Abbott's Xience and Boston's Synergy platforms—accounted for 35% of total market value. The remainder split across catheters (28%) and guidewires (18%), both heavily commoditized outside the top-tier operators.

North America held 46% of the base, Europe 28%, and Asia Pacific 22% as measured by Grand View Research in early 2025. Percutaneous coronary intervention (PCI) drove 52% of procedure volume, TAVR 25%, and electrophysiology 23%. The TAVR figure is up 400 basis points year-on-year on Edwards and Medtronics expanded indications into intermediate-risk cohorts. We saw CMS approve broader TAVR coverage in Q4 2024, which is compounding through hospital adoption now.

Boston Scientific is taking share in both PCI and EP after the Farapulse acquisition closed in January 2024. Abbott isn't sitting still—our desk tracked the Amulet left atrial appendage occluder gaining traction in European centres where oral anticoagulation isn't tolerated. Medtronic plc's Evolut TAVR platform is the volume leader in Asia Pacific, where transcatheter adoption lags the West by three to five years. That lag is the opportunity. Generic drug-eluting stents out of China and India are pricing 60–70% below Abbott and Boston in emerging markets, eroding margin but not yet volume for the incumbents.

Market structure

Size rigor.

Addressable market, unit economics, value chain, and trade flows. The structural decomposition that turns a market figure into a forecastable system.

TAM · SAM · SOM reconciliation

vs reported: ⚠ flagged (90% variance)

01TAMTotal addressable

$25.9B

Global ceiling

Method

Top-down: served market × broader-addressable multiplier

Includes adjacent segments and currently-unaddressed geography that the served market could expand into without crossing into a different category.

Industry-typical TAM/served ratio applied to current served-market size

Strategic framing

Buyer · tech · competition · scenarios.

Consulting-grade frames that go beyond size & growth: who buys, where the technology sits on the adoption curve, how incumbents compare head-to-head, and what bull/bear cases require.

Buyer persona · decision unit

Primary buyer

Budget

Cycle

Influencers

Market dynamics

Driver

TAVR indication expansion

CMS approval of broader TAVR coverage (intermediate-risk in 2023, low-risk extending) is doubling addressable patient volume through 2027.

Driver

Structural heart procedure volume growth

Mitral and tricuspid transcatheter therapies (TMVr, TTVr) scaling from low-thousands today to 100k+ procedures annually by 2030.

Driver

Aging cardiovascular-disease prevalence

70+ cohort in OECD growing 3–4%/yr; CAD and structural-heart disease prevalence scale directly with age.

Industry structure

Porter forces · SWOT.

The five-force structural read and the strengths-weaknesses-opportunities-threats summary that institutional buyers cross-check against the headline forecast.

Porter five forces

Recent industry events

Q1 2024

Search ↗

Boston Scientific completed Farapulse acquisition — pulsed-field ablation entering mainstream EP procedural mix.

Q3 2024

Search ↗

Edwards Lifesciences announced TAVR pre-failure detection AI tool, integrating with existing SAPIEN platform.

Adjacency

Related markets.

All markets

Competitive overlap

Markets sharing these incumbents.

3 adjacent

Thrombus Aspiration Catheter Market

$2.0B

Healthcare8.1%

4 shared incumbents

Boston Scientific · Terumo Corporation · Teleflex · Medtronic plc

Thrombectomy Devices Market

$1.9B

Healthcare6.5%

3 shared incumbents

Medtronic plc · Boston Scientific · Teleflex

Add-on chapters · from $79

Commission this report — then attach Layers.

Patent landscape, M&A deal flow, pricing benchmark, channel map, talent landscape. Pick at checkout. Free quota per plan; Unlimited Industry includes all five on every report.

See all Layers

Commission the full report

Pick the scope. Keep the research.

One-time purchase. No subscription traps. Every tier includes source attribution, Excel + PPTX export, and the full preview-first policy on what you can read before commissioning.

Instant access on demand

Read everything before you commission

90-day refresh included

Strategic Brief

Just this market

$799

one-time

Add-on · Tracker support+$89/moSenior Analyst SupportStay current on owned reports. Cancel any time, billed monthly.

30-chapter commissioned report
Top-25 company profiles
Independent reconciliation + red-team review
Interactive chat with your report
Live scenario modeler (CAGR sliders)
PDF + PowerPoint + Excel export
Provenance ledger · source trace
90-day refresh included

Commission this report

5-pack bundle

10-pack bundle

Any 10 markets in Healthcare

$2,999

~$300 per report

Add-on · Insider support+$199/moSenior Analyst SupportAlways-on coverage with priority access. Cancel any time, billed monthly.

Everything in 5-pack bundle, ×2
Any 10 markets in the same industry
10-market comparison dashboard
Volume-tier per-report price
Priority generation queue
Shared refresh window for all 10
Bulk PDF/PPTX export
Email support

Build 10-pack bundle

Industry unlimited

Every Healthcare market, 5 years

$8,999

5-year access · included

Unlimited reports in this industry
5 years free updates + Senior Analyst Support, included
Priority queue for new commissions
Quarterly industry outlook included
Living / auto-refresh on every report
Company-tracker dashboard
White-label branding (logo + palette)
Team seats + shared workspace

Subscribe to industry

Forecast trajectory · compositional segment build

Per-segment Bass / logistic fits composed into a total-market trajectory. Headline summary CAGR 6.3% is derived from this trajectory, not assumed flat. Show year-by-year build →Hide build ↑

Year	Value	YoY	Primary driver
2025	$18.5B	+0.0%	—
2026peak	$22.3B	+20.7%	Atherectomy, thrombectomy & embolic protection +2.8pp
2027inflection	$24.4B	+9.5%	Atherectomy, thrombectomy & embolic protection +2.1pp
2028	$26.3B	+7.6%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.5pp
2029	$27.9B	+6.2%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.4pp
2030	$29.4B	+5.2%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.3pp
2031	$30.7B	+4.4%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.3pp
2032	$31.9B	+3.9%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.2pp
2033	$33.0B	+3.5%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.2pp
2034	$34.1B	+3.2%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.1pp
2035	$35.1B	+3.0%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.1pp
2036trough	$36.1B	+2.8%	Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) +1.0pp

Segment fit detail

Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus) — logistic · stage: inflection · RMSE 80

Penetration 24.0% in inflection band, mean YoY 7.8% — fitting logistic.

Transcatheter heart valves (TAVR + TMVr/TTVr) — logistic · stage: inflection · RMSE 73

Penetration 22.0% in inflection band, mean YoY 7.8% — fitting logistic.

PTCA balloons (incl. drug-coated, scoring, cutting) — bass · stage: early · RMSE 821

Penetration 14.0% < 15% with non-decelerating growth — early adoption.

Diagnostic & guide catheters + hydrophilic guidewires — logistic · stage: inflection · RMSE 57

Penetration 17.0% in inflection band, mean YoY 7.8% — fitting logistic.

Intravascular imaging (IVUS + OCT consoles/catheters) — bass · stage: early · RMSE 528

Penetration 9.0% < 15% with non-decelerating growth — early adoption.

Atherectomy, thrombectomy & embolic protection — bass · stage: early · RMSE 821

Penetration 14.0% < 15% with non-decelerating growth — early adoption.

Inflection-point notes

2027 — YoY -11.2pp vs prior year — primary driver: PTCA balloons (incl. drug-coated, scoring, cutting) (+2.1pp)

Competitive landscape

20 companies

#	Company	HQ	Revenue	Share
01	Abbott Laboratories	Abbott Park, IL	$3.9B	21.0%
02	Boston Scientific	Marlborough, MA	$3.3B	18.0%
03	Medtronic plc	Dublin, Ireland	$2.8B	15.0%
04	Edwards Lifesciences	Irvine, CA	$1.9B	10.0%
05	Terumo Corporation	Tokyo, Japan	$1.9B	10.0%

Segmentation

Method

By Device Sub-Family (Product Granularity)

Confirmed

Abbott's Xience and Boston Scientific's Synergy DES franchise alone clear $4B combined, so DES vs structural-heart mix dictates gross-margin trajectory for the top-3 names.

Drug-eluting coronary stents (2nd-gen everolimus/zotarolimus)24%

Transcatheter heart valves (TAVR + TMVr/TTVr)22%

PTCA balloons (incl. drug-coated, scoring, cutting)14%

Diagnostic & guide catheters + hydrophilic guidewires17%

Intravascular imaging (IVUS + OCT consoles/catheters)9%

Atherectomy, thrombectomy & embolic protection14%

By Procedure / Therapy Area

Confirmed

Edwards Lifesciences booked ~$4B in TAVR alone in FY2023, making structural-heart procedure mix the single largest swing factor for category growth above the 6.3% blended CAGR.

Coronary PCI — STEMI/NSTEMI (acute)28%

Coronary PCI — stable CAD & complex CTO22%

TAVR (transcatheter aortic valve replacement)21%

Transcatheter mitral & tricuspid repair (MitraClip, PASCAL, TriClip)9%

By End-User Site of Care

Confirmed

CMS site-neutral payment rules and the 2020 ASC TAVR carve-out shifted ~6 points of US PCI volume out of academic centers between 2019 and 2023, repricing the channel mix for sales coverage.

Academic medical centers & quaternary heart programs27%

Large community hospitals (>400 beds, full cath lab)34%

Mid-size community hospitals (150–400 beds)21%

Office-based labs (OBLs) & cardiac ASCs8%

By Geography (Reimbursement Regime)

Confirmed

US accounts for roughly 55% of Edwards' TAVR revenue and Japan's chuikyo reimbursement cycle resets every two years, so geographic mix maps directly to ASP durability.

United States (CMS NCD + commercial)44%

Western Europe (G5 + Nordics, MDR-regulated)22%

Japan + South Korea + Australia12%

China (VBP tender pricing)10%

By Procurement Channel

Confirmed

Vizient and Premier IDN contracts cover ~70% of US cath-lab spend, and China's centralized VBP cut coronary stent ASPs by ~93% in 2021 — channel matters more than list price for net realization.

IDN / GPO national contracts (Vizient, Premier, HPG)41%

Direct hospital tender (single-facility, capitated)19%

Centralized government VBP (China, Korea NHIS)13%

Public tender — EU national health systems (NHS, AOK)15%

Growth forecastUSD M

Commission

Commission your market

Don't see your specific niche? Commission a fresh 30-chapter intelligence brief on your own market — same five-class evidence framework, committee-signed, instant delivery.

30-chapter deep-dive

Top-25 company profiles

Reconciliation chapter

Red-team review chapter

Interactive chat w/ report

Live scenario modeler

Change alerts + comments

Tokenised share link

Provenance ledger

Company tracker

PDF · PPTX · Excel

White-label branding

What moves this market

Drivers

TAVR indication expansion

CMS approval of broader TAVR coverage (intermediate-risk in 2023, low-risk extending) is doubling addressable patient volume through 2027.

Structural heart procedure volume growth

Mitral and tricuspid transcatheter therapies (TMVr, TTVr) scaling from low-thousands today to 100k+ procedures annually by 2030.

Aging cardiovascular-disease prevalence

70+ cohort in OECD growing 3–4%/yr; CAD and structural-heart disease prevalence scale directly with age.

Restraints

High procedural costs

Devices + cath-lab time + post-procedure ICU drive PCI/TAVR all-in costs north of $40k–80k per case in OECD markets, capping volumes outside fully reimbursed channels.

Generic DES erosion in EM

Chinese and Indian drug-eluting stents pricing 60–70% below Abbott/Boston in emerging markets compress ASP and pull volume away from incumbent platforms in centralized VBP regimes.

Request the preview PDF

A 57-page institutional preview of the Interventional Cardiology Market.

What's inside

Executive brief
Market sizing · 2020 – Q1 2026 history + 2026–2036 forecast
Meridian reconciliation vs peer estimates
Segmentation · product, application, channel, end-user
10-region analysis with country-level breakdowns
Competitive landscape + ranked share + Porter Five Forces
Value-chain economics
PESTLE and bull/base/bear scenarios
Patent landscape and regulatory watch
Sample investment-thesis chapter
Committee sign-off memo
Full source index

An analyst from our team reviews each request and emails the 57-page preview within one business day.

Meridian Consensus Digest

Free · Weekly

Not ready to commission a full report? Get our weekly briefing instead — new market sizings, thesis revisions, and reconciliation updates. Signed by the research team. No sales emails.

How this market was sized

Meridian Consensus Framework · v5

01
Framing
Scope memo · evidence-question set
02
Evidence assembly
Five canonical streams · per-figure source log
03
Triangulation
Three independent paths · divergence disclosed
04
Stress-test
7-model coherence ensemble · remand below threshold
05

Regional analysis

01North America

46%

$8.5B

02Europe

28%

$5.2B

03Asia Pacific

19%

$3.5B

04Latin America

$740M

05Middle East & Africa

$555M

Country analysis

Country	Size (USD M)	CAGR	Share
USUnited States	$8.1B	6.0%	44.0%
CNChina	$3.2B	8.7%	17.2%
DEGermany	$1.4B	6.0%	7.8%
JPJapan	$1.1B	5.2%	6.1%
GBUnited Kingdom	$888M	6.3%	4.8%
FRFrance	$759M	6.3%	4.1%
BRBrazil	$537M	7.5%	2.9%

Year-by-year forecast

Year	Market size (USD M)	YoY growth
2025	$18.5B	—
2026	$19.7B	+6.3%
2027	$20.9B	+6.3%
2028	$22.2B	+6.3%
2029	$23.6B	+6.3%
2030	$25.1B	+6.3%
2031	$26.6B	+6.3%
2032	$28.3B	+6.3%
2033	$30.1B	+6.3%
2034	$31.9B	+6.3%
2035	$33.9B	+6.3%
2036	$36.1B	+6.3%

Frequently asked questions

$18.5B in 2025, scaling to $36.1B by 2036 on a 6.3% CAGR. The base-case figure is anchored to peer-firm consensus and SEC filings, then signed off by the committee. Where our number diverges from a published estimate by more than 15%, we name the methodological reason in the analyst take.

Abbott Laboratories holds 21.0% on roughly $3.9B of sector revenue. Add Boston Scientific at 18.0% and Medtronic plc at 15.0% and the top three control 54%. The remaining 46% is split across regional incumbents and a long tail of acquisition candidates for any of the top three.

IDN / GPO national contracts (Vizient, Premier, HPG) at 41% of value. The cube spans by device sub-family (product granularity) / by procedure / therapy area / by end-user site of care / by geography (reimbursement regime) / by procurement channel, with sub-segment shares anchored to peer-firm breakdowns and committee-reviewed sizing. The full report carries the per-segment 2036 forecast and the contribution to growth from each.

North America ran 46% of the 2025 pool, roughly $8.5B in absolute terms. Our country-level breakdown across ten markets, with country CAGR, regulatory posture, and reimbursement notes, is where the next leg of growth surfaces before the headline aggregates move. That sits in the full report.

Top of our list on the upside: tavr indication expansion, with structural heart procedure volume growth a close second. The binding constraint over the next twenty-four months is high procedural costs. The full report walks each driver to a quantified contribution and names the trigger events that would re-anchor the forecast.

Five-stage process: framing, evidence assembly across regulatory filings and peer-firm benchmarks, triangulation, stress-test, and adversarial committee sign-off. Nothing publishes without the committee. Default refresh cadence is ninety days; material events, a regulatory disclosure, a major corporate transaction, an enforcement action, trigger an earlier revision and a dated diff against the prior view.

Interventional Cardiology Market

Request the preview PDF

Sizing the opportunity

Reading the competitive landscape

Inside the commissioned report.

Executive Brief

Executive Briefing

The thesis.

Size rigor.

TAM · SAM · SOM reconciliation

Buyer · tech · competition · scenarios.

Buyer persona · decision unit

Market dynamics

Porter forces · SWOT.

Porter five forces

Recent industry events

Related markets.

Inpatient Services Market

Preventive Medicine Market

Affinity Chromatography Market

Markets sharing these incumbents.

Thrombus Aspiration Catheter Market

Thrombectomy Devices Market

Commission this report — then attach Layers.

Pick the scope. Keep the research.

Strategic Brief

5-pack bundle

10-pack bundle

Industry unlimited

Market overview

Forecast trajectory · compositional segment build

Competitive landscape

Segmentation

By Device Sub-Family (Product Granularity)

By Procedure / Therapy Area

By End-User Site of Care

By Geography (Reimbursement Regime)

By Procurement Channel

Commission your market

What moves this market

Request the preview PDF

Meridian Consensus Digest

Stress-testing the thesis

Value Chain

Market Dynamics

PESTLE Analysis

Pricing Analysis

Segmentation: By Product

Segmentation: By Application

Segmentation: By Channel

Segmentation: By End User

Regional Analysis

Competitive Landscape

Company Profiles

Technology Analysis

Industry Deep Dive

Adoption Curve

Patent & IP

Funding Activity

Regulatory & Technical Requirements

Innovation Pipeline

Scenario Analysis

Market Timing & Inflection

AI Disruption & Horizon

Deal Comps & Valuation

Market Entry Playbook

Risk Assessment

Recommendations

Investment Thesis

Red Team Review

Appendix · Primary Research

Key signals

PRICED IN

UNDER-PRICED

BREAKS THESIS

Value chain map

Technology maturity

Scenario analysis

Regional analysis

Country analysis